{"id":987501719,"date":"2025-10-23T14:31:56","date_gmt":"2025-10-23T14:31:56","guid":{"rendered":"https:\/\/boracdmo.com\/bora-pharmaceuticals-expands-offerings-with-new-state-of-the-art-production-line-2\/?lang=en"},"modified":"2026-03-16T21:43:11","modified_gmt":"2026-03-16T21:43:11","slug":"bora-pharmaceuticals-leverages-state-of-the-art-isolator-production-line-to-scale-supply-of-vital-oncology-therapy","status":"publish","type":"post","link":"https:\/\/boracdmo.com\/bora-pharmaceuticals-leverages-state-of-the-art-isolator-production-line-to-scale-supply-of-vital-oncology-therapy\/","title":{"rendered":"Bora Pharmaceuticals Leverages State-of-the-Art Isolator Production Line To Scale Supply of Vital Oncology Therapy"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

 <\/span>Isolator line provides U.S.-based fill\/finish capacity for partners<\/i><\/p>

in oncology and specialty drug manufacturing<\/i><\/p>
<\/h3>\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

BALTIMORE<\/strong> (October 23, 2025) <\/strong>— Bora Pharmaceuticals Co., Ltd.<\/a> (\u201cBora\u201d or \u201cthe Company\u201d, TWSE: 6472), a global leader in pharmaceutical manufacturing, will leverage its Groninger\u00ae FlexPro 50 Isolator Line for Vials & Pre-filled Syringes to continue to broaden patients\u2019 access to lifesaving treatments and therapies.<\/p>

\u00a0<\/p>

Bora combines its long-standing CDMO expertise in aseptic fill\/finish capabilities for vials and pre-filled syringes with the latest isolator technology and industry knowledge to support key partners, including Accord BioPharma, Inc., with large-scale production of critical therapies.<\/p>

\u00a0<\/p>

\u00a0<\/p>

Bora has partnered with Accord BioPharma to manufacture pre-filled syringes of UDENYCA\u00ae (pegfilgrastim-cbqv), a product recently added to Accord\u2019s portfolio. The isolator line at the Baltimore site will help scale supply of the vital therapy to support immune health in cancer care.<\/p>

\u00a0<\/p>

\u00a0<\/p>

\u201cWe\u2019re excited to combine Bora\u2019s manufacturing expertise with Accord\u2019s desire to increase production to meet demand and manufacture in the United States.\u201d said David Fidler, Vice President and General Manager of Bora Pharmaceuticals Baltimore. \u201cOur team\u2019s deep technical knowledge will play a vital role in accomplishing these goals.\u201d<\/p>

\u00a0<\/p>

\u00a0<\/p>

From early development and scale-up to process optimization and commercial manufacturing, Bora\u2019s experienced teams support customers at every stage of the product lifecycle. The company\u2019s commercial on-time, in-full (OTIF) delivery record is unmatched, reinforcing Bora\u2019s role as a trusted partner, supporting clients with secure, consistent supply. For more information, visit boracdmo.com<\/a>.<\/p>

\u00a0<\/p>

\u00a0<\/p>

###<\/p>

\u00a0<\/p>

\u00a0<\/p>

About Bora Pharmaceuticals<\/strong><\/p>

Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit www.boracdmo.com<\/a>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

 Isolator line provides U.S.-based fill\/finish capacity for partners in oncology and specialty drug manufacturing BALTIMORE (October 23, 2025) — Bora Pharmaceuticals Co., Ltd. (\u201cBora\u201d or \u201cthe Company\u201d, TWSE: 6472), a global leader in pharmaceutical manufacturing, will leverage its Groninger\u00ae FlexPro 50 Isolator Line for Vials & Pre-filled Syringes to continue to broaden patients\u2019 access to […]<\/p>\n","protected":false},"author":9,"featured_media":987501711,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[58],"tags":[69],"class_list":["post-987501719","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-business"],"aioseo_notices":[],"acf":[],"_links":{"self":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987501719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/comments?post=987501719"}],"version-history":[{"count":6,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987501719\/revisions"}],"predecessor-version":[{"id":987501728,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987501719\/revisions\/987501728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/media\/987501711"}],"wp:attachment":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/media?parent=987501719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/categories?post=987501719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/tags?post=987501719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}